GYRE
Gyre Therapeutics Inc.
NASDAQ: GYRE · HEALTHCARE · BIOTECHNOLOGY
$7.68
+4.49% today
Updated 2026-04-30
Market cap
$696.73M
P/E ratio
381.50
P/S ratio
5.98x
EPS (TTM)
$0.02
Dividend yield
—
52W range
$7 – $12
Volume
0.1M
Gyre Therapeutics Inc. (GYRE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
4.31%
Operating margin
0.32%
ROE
8.21%
ROA
4.93%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $27.54M | $2.10M | 98.34% | -1.47% | 7.61% |
| 2007 | $11.58M | $-28.07M | 93.82% | -274.46% | -242.51% |
| 2008 | $20.09M | $-25.66M | 96.27% | -140.12% | -127.76% |
| 2009 | $25.06M | $-39.40M | 97.24% | -160.90% | -157.23% |
| 2010 | $85.71M | $10.90M | 100.00% | 15.30% | 12.72% |
| 2011 | $97.64M | $-8.53M | 100.00% | -9.98% | -8.74% |
| 2012 | $57.86M | $-7.00M | 100.00% | -14.06% | -12.09% |
| 2013 | $3.63M | $-46.70M | -80.68% | -1,301.07% | -1,286.99% |
| 2014 | $275000.00 | $-32.62M | -1,815.27% | -10,805.09% | -11,862.91% |
| 2015 | $1.75M | $-14.76M | -240.46% | -788.69% | -843.54% |
| 2016 | $399000.00 | $-16.95M | -2,545.36% | -5,117.29% | -4,246.87% |
| 2017 | $1.02M | $-21.56M | -1,161.98% | -2,143.61% | -2,117.98% |
| 2018 | $6000.00 | $-30.05M | -357,800.00% | -563,700.00% | -500,916.67% |
| 2019 | — | $-55.18M | — | — | — |
| 2020 | $20.95M | $-55.54M | 56.26% | -273.87% | -265.14% |
| 2021 | $7.34M | $-87.93M | -4.52% | -1,140.99% | -1,198.32% |
| 2022 | $102.29M | $2.30M | 95.31% | 9.00% | 2.25% |
| 2023 | $113.45M | $-92.93M | 95.91% | -59.26% | -81.92% |
| 2024 | $105.76M | $12.09M | 96.33% | 15.28% | 11.43% |
| 2025 | $116.59M | $5.03M | 95.35% | 9.85% | 4.31% |